Edition:
United States

La Jolla Pharmaceutical Co (LJPC.OQ)

LJPC.OQ on NASDAQ Stock Exchange Capital Market

24.29USD
14 Dec 2017
Change (% chg)

$-2.30 (-8.65%)
Prev Close
$26.59
Open
$26.90
Day's High
$26.90
Day's Low
$23.90
Volume
165,367
Avg. Vol
108,254
52-wk High
$39.26
52-wk Low
$16.43

Chart for

About

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant... (more)

Overall

Beta: 1.70
Market Cap(Mil.): $537.91
Shares Outstanding(Mil.): 22.15
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 190.77 15.47
EPS (TTM): -- -- --
ROI: -- -11.61 33.71
ROE: -- -35.87 16.38

BRIEF-La Jolla Pharma files for mixed shelf of up to $150 mln ‍​

* Files for mixed shelf of up to $150 million - SEC filing‍​ Source text : [http://bit.ly/2zK9cPg] Further company coverage:

Oct 27 2017

BRIEF-La Jolla reports Q3 loss $1.19/shr

* La Jolla Pharmaceutical Company announces financial results for the three and nine months ended September 30, 2017 and recent corporate progress

Oct 26 2017

BRIEF-Prudential Financial reports 10.1 pct passive stake ​in La Jolla Pharmaceutical

* Prudential Financial Inc reports 10.1 percent passive stake ​in La Jolla Pharmaceutical Co as of Sept 30 - sec filing ‍ Source text : [http://bit.ly/2g07Ckv] Further company coverage:

Oct 10 2017

BRIEF-La Jolla Pharmaceutical Co announces intent to submit Marketing Authorization Application for LJPC-501

* La Jolla Pharmaceutical Company announces intent to submit Marketing Authorization Application for LJPC-501 in the third quarter of 2018 Source text for Eikon: Further company coverage:

Sep 25 2017

BRIEF-FDA accepts La Jolla Pharmaceutical's NDA for LJPC-501

* La Jolla Pharmaceutical Company announces U.S. Fda acceptance of new drug application for LJPC-501

Aug 28 2017

BRIEF-La Jolla Pharma ‍announces launch of expanded access program for LJPC-501​

* La Jolla Pharmaceutical Co - ‍announces launch of expanded access program for LJPC-501​ Source text for Eikon: Further company coverage:

Aug 08 2017

BRIEF-La Jolla Pharmaceutical reports CEO compensation

* CEO George Tidmarsh's 2016 total compensation was $4.7 million versus $15.6 million in 2015 - SEC filing Source text for Eikon: Further company coverage:

Jul 31 2017

BRIEF-La Jolla quarterly loss per share $1.21

* La Jolla Pharmaceutical Company announces financial results for the three and six months ended June 30, 2017 and recent corporate progress

Jul 27 2017

Competitors

Earnings vs. Estimates